• Institute of Good Manufacturing Practices India
  • Global accredited training & certification provider
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India
  • Approved Training Institute of Food Safety and Standards Authority of India (FSSAI)
  • Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017

Trusted by organizations & training participants in over 30 countries
Training | Certification | Education | Research

Guidance on Good Manufacturing Practice for APIs finalized by FDA

The FDA has finalized the guidance on Good Manufacturing Practice (GMP) for active pharmaceutical ingredients (APIs) which is based on the International Conference on Harmonization (ICH Q7) guidelines. The revised guideline is based on question and answer format so that responses can be provided to requests for clarification of uncertainties due to interpretation of certain sections in the ICH guidance.

The guidance provides GMP for the manufacture of APIs under an appropriate system for managing quality and to help companies ensure that APIs meet the quality and purity characteristics.

According to the guidance annual product reviews is generally expected by FDA however time frames can be adjusted to more or less than 12 months depending upon product campaign duration. In the guidance FDA makes it clear that irrespective of whether the manufacturing took place or not during the review period, the product quality reviews should still be carried on and should include complaints, returns, recalls and stability, as well as trend analysis. In 2017, The European Medicines Agency and FDA both agreed to carry out GMP inspections of pharmaceutical manufacturing sites conducted in their respective territories on both sides of the Atlantic.